Chemistry:ZLY18
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C25H23FO6 |
| Molar mass | 438.451 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ZLY18 is an experimental drug that acts as an agonist of the free fatty acid receptor 1 (FFA1) and all three types of peroxisome proliferator-activated receptor (alpha, delta, and gamma). It is in development for the treatment of non-alcoholic fatty liver disease.[1][2][3][4]
References
- ↑ Zhou, Zongtao; Ren, Qiang; Jiao, Shixuan; Cai, Zongyu; Geng, Xinqian; Deng, Liming; Wang, Bin; Hu, Lijun et al. (5 February 2022). "Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents". European Journal of Medicinal Chemistry 229: 114061. doi:10.1016/j.ejmech.2021.114061. ISSN 1768-3254. PMID 34954593. https://pubmed.ncbi.nlm.nih.gov/34954593/.
- ↑ Xu, Xiaohan; Poulsen, Kyle L.; Wu, Lijuan; Liu, Shan; Miyata, Tatsunori; Song, Qiaoling; Wei, Qingda; Zhao, Chenyang et al. (2022). "Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)" (in en). Signal Transduction and Targeted Therapy 7 (1): 287. doi:10.1038/s41392-022-01119-3. ISSN 2059-3635. PMID 35963848.
- ↑ Gong, Lijun; Wei, Fang; Gonzalez, Frank J.; Li, Guolin (2023). "Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines". Hepatology 78 (5): 1625–1653. doi:10.1097/HEP.0000000000000182. PMID 36626642.
- ↑ Statham, Laura; Pelling, Melina; Hanson, Petra; Kyrou, Ioannis; Randeva, Harpal; Barber, Thomas M (4 May 2023). "Designer GLP1 poly-agonist peptides in the management of diabesity". Expert Review of Endocrinology & Metabolism 18 (3): 231–240. doi:10.1080/17446651.2023.2204976. PMID 37089108.
 |  |
